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 More than just side effects: the role of clinical and psychosocial factors in non-adherence to 
tamoxifen  
 
Objectives: Tamoxifen non-adherence is apparent in up to half of breast cancer survivors and is 
associated with increased risk of recurrence and reduced quality of life. However, factors contributing 
to non-adherence in this population are currently poorly understood. This study explored the 
relationship between key components of the Common Sense Model of Illness Representations (CSM) 
/ the Theory of Planned Behaviour (TPB) and intentional and unintentional non-adherence in a large 
sample of women prescribed tamoxifen following primary breast cancer.  
Design: Cross-sectional questionnaire study (n=777).  
Methods: Women were eligible if they were over 18, had been diagnosed with primary breast 
cancer and had been prescribed tamoxifen. Participants were recruited in clinic or online and 
completed questionnaires assessing illness perceptions, treatment beliefs, adherence, quality of life, 
social support, distress and the key TPB components. Logistic regressions were conducted to test 
elements from each model and to identify correlates of intentional and unintentional non-adherence.  
Results: Patients were classified as non-adherent based on Medication Adherence Rating Scale 
scores. 44% of the population were non-adherent; 41% reported unintentional non-adherence and 9% 
reported intentional non-adherence. Study variables accounted for more variance in intentional 
(Nagelkerke R2 = 46%) than unintentional non-adherence (Nagelkerke R2=17%). Intentional non-
adherence was best explained by a combination of TPB and CSM variables, but these variables did 
not contribute significantly to unintentional non-adherence.   
 Conclusions: The TPB and the CSM provide a useful framework for understanding intentional 
tamoxifen non-adherence. Elements from both models should be considered when designing 








Breast cancer is the most common cancer in women in the UK, and whilst survival rates are 
improving, it is still the second most common cause of cancer-related death in the UK (Cancer 
Research UK, 2014). About 75% of breast cancers are oestrogen receptor positive (ER+), which 
means the cancer cells are stimulated by oestrogen (Harrell et al., 2007). Adjuvant hormonal therapy 
(HT) such as tamoxifen is prescribed to women with ER+ breast cancer to reduce the risk of 
recurrence. Tamoxifen, which works by blocking the oestrogen receptor, reduces the risk of 
recurrence by 46% and the risk of mortality by 26% (Early Breast Cancer Trialists' Collaborative 
Group, 1998). It is prescribed for between five and ten years and is one of the most effective systemic 
therapies available for ER+ early breast cancer (Aguilar et al., 2010).  
Treatment adherence, defined as the extent to which patients take their medication as prescribed 
(Sabate, 2003), is often not considered to be an issue with cancer patients, due to the life threatening 
nature of the illness (Wu, Stafkey-Mailey, & Bennett, 2012). However, despite the clear clinical 
benefits of tamoxifen, many patients either stop taking their medication early or do not take the full 
dosage. Non-adherence ranges from 6% - 55% (Ayres, Baldoni, Borges, & Leira Pereira, 2014; 
Hershman et al., 2011; McCowan, Wang, Thompson, Makubate, & Petrie, 2013) and rises over time 
(Hershman et al., 2010; Partridge, Wang, Winer, & Avorn, 2003). This variability in adherence rates 
is likely due to variations in study design and populations, such as different healthcare and cultural 
contexts. Furthermore, there is significant variability in the tools used to assess adherence, with 
studies utilizing self-report measures reporting higher rates of adherence (Moon et al., 2017). A 
further 50% of patients completely discontinue tamoxifen within five years (Kostev et al., 2013; van 
Herk-Sukel et al., 2010), which is known as non-persistence. Non-adherence and non-persistence to 
tamoxifen are associated with increased risk of death and early recurrence (Barron, Cahir, Sharp, & 
Bennett, 2013; Hershman et al., 2011; Makubate, Donnan, Dewar, Thompson, & McCowan, 2013), as 
well as fewer quality adjusted life years and increased medical costs (McCowan et al., 2013). This 
indicates a need to understand why women are not adhering, so we can intervene to increase 
adherence rates and improve clinical outcomes. Identifying psychosocial predictors of non-adherence 
is essential in the development of interventions, as these factors have the potential to be modified. For 
example, medication beliefs and perceived control over medication taking are associated with 
medication adherence in a range of conditions (Conner, Black & Stratton, 1998; Horne & Weinman, 
1999) and have been successfully targeted in interventions (Petrie et al., 2012; Sheeran & Orbell, 
2000).   However, evidence on modifiable psychological predictors of tamoxifen adherence is 
currently lacking (Moon, Moss-Morris, Hunter, Carlisle, & Hughes, 2017; Murphy, Bartholomew, 
Carpentier, Bluethmann, & Vernon, 2012), with an emphasis in the literature on non-modifiable 
clinical and demographic factors.   
Non-adherence can be conceptualised as intentional, where the patient makes a deliberate decision not 
to adhere, or unintentional, where they may forget or not understand the instructions. Unintentional 
non-adherence is more prevalent in breast cancer, however this may be due to forgetting being more 
socially acceptable and therefore more frequently reported (Atkins & Fallowfield, 2006; Unni & 
Farris, 2011). Some studies suggest that unintentional non-adherence may be related to medication 
beliefs (Gadkari & McHorney, 2012; Schüz et al., 2011), which questions how unintentional these 
behaviours are. However, recent studies in breast cancer have supported the idea of a distinction 
between unintentional and intentional non-adherence (Kimmick et al., 2015; Wouters et al., 2014). 
Understanding these different types of non-adherence and the associated predictors would be useful in 
tailoring interventions to improve adherence.  
Tamoxifen is associated with side-effects, including hot flushes, vaginal dryness and low mood, 
which are often assumed to drive non-adherence. However, the relationship between side-effects and 
non-adherence is inconsistent (Moon et al., 2017). Whilst a recent systematic review has found some 
evidence for potentially modifiable psychosocial correlates of HT non-adherence, including self-
efficacy for medication taking, medication beliefs and social support (Moon et al., 2017), previous 
research has largely failed to use theoretical models when investigating non-adherence. Theory 
provides a structured framework for investigating key determinants of non-adherence and helps with 
intervention development (Holmes, Hughes, & Morrison, 2014). This study will use two popular 
models of health behaviour to investigate tamoxifen non-adherence; the Common Sense Model 
(CSM) and the Theory of Planned Behaviour (TPB). These models have been used extensively to 
predict health behaviours, but to the best of our knowledge, no peer reviewed research has applied 
them to tamoxifen adherence.  
The TPB proposes that adherence is driven by intentions to engage with treatment, which are in turn 
influenced by subjective norms, attitudes and perceived behavioural control (PBC), which also exerts 
a direct influence over behaviour (Ajzen, 1991). Previous studies have supported the TPB as a 
framework for understanding non-adherence (Kagee & Van der Merwe, 2006) with key TPB 
variables explaining large proportions of variance in medication adherence (Bane, Hughe, & 
McElnay, 2010; Conner et al., 1998). The CSM proposes that patients hold illness representations, or 
implicit common sense beliefs about their illness, which are used as a framework for making sense of 
and coping with an illness (Leventhal, Diefenbach, & Leventhal, 1992). Key illness perceptions are 
identity (the label given to the illness and symptoms experienced), causal beliefs, timeline beliefs, 
treatment control, personal control and consequences. Patients also hold emotional representations of 
their illness. These illness perceptions have been associated with adherence in several studies, 
highlighting the utility of the CSM as a framework for investigating non-adherence (Brewer, 
Chapman, Brownlee, & Leventhal, 2002; Patel & Taylor, 2002; Ross, Walker, & MacLeod, 2004). 
The CSM is a dynamic model where illness perceptions affect selection of coping strategies, and the 
outcome of these coping strategies affects illness perceptions. The explanatory power of the CSM has 
been improved by the addition of medication beliefs, which may act as a more proximal determinant 
of non-adherence. These medication beliefs include concerns, and necessity beliefs, which relate to 
how necessary the patient feels the medication is for their current and future health. Necessity and 
concern beliefs are stronger predictors of adherence than clinical or demographic factors (Horne & 
Weinman, 1999). The differential between necessity and concern beliefs is often used to predict non-
adherence and represents a cost-benefit analysis patients may undergo before making decisions about 
treatment (Horne & Weinman, 1999; Wileman et al., 2011). This framework also includes more 
general beliefs about medication, but the specific beliefs (necessity/concerns) have been shown to be 
more important in relation to medication adherence (Grunfeld et al., 2005; Horne & Weinman, 1999; 
Zwikker et al., 2014a).  
The primary aim of this study was to explore the relationship between key aspects of the CSM and 
TPB and both intentional and unintentional non-adherence, in order to facilitate the development of 
interventions to improve adherence. Elements from both models were included to heighten the 
explanatory power and to explore both perceptions around cancer survivorship (CSM) and the 
medication taking behaviour itself (TPB), as it was felt that both these sets of variables may have an 
influence on non-adherence. Testing both models concurrently allows for a broader range of predictor 
variables to be tested, and may allow for creation of a more parsiminous model. Demographic, 
clinical and other psychosocial variables such as distress and social support were controlled for in the 
analysis as they have previously shown associations with tamoxifen non-adherence (Moon et al., 
2017). Based on previous research, we hypothesise  that unintentional non-adherence will be reported 
more frequently than intentional non-adherence, and that psychological variables from the CSM 
andTPB, such as necessity and concern beliefs, will be related more to intentional than unintentional 
non-adherence.  
As adherence rates fall across time (Nekhlyudov, Li, Ross-Degnan, & Wagner; Schover, Baum, 
Fuson, Brewster, & Melhem-Bertrandt, 2014),  a secondary aim was to investigate whether adherence 
was higher in women who were nearer the beginning of treatment. Differences in CSM and TPB 
variables between women within six months of treatment and women who are later on in treatment 
were also explored, to provide understanding of how illness or treatment beliefs differ across the 
treatment trajectory. Little is currently known about the illness beliefs held by these patients or how 
they may change over time.  
Method  
Participants and procedure  
The study was approved by the Northampton National Research Ethics Committee (REF 
14/EM/1207). Women were eligible for the study if they were over 18, had been diagnosed with 
primary breast cancer and had been prescribed tamoxifen. Patients were recruited through 27 
oncology clinics across England and through online advertisements. In clinic, eligible women were 
identified by clinic staff and were told about the research during their appointment. Patients were 
given an information sheet and consent form as well as verbal information about the study. They 
could complete the questionnaire in clinic, take it away and return it using a stamped addressed 
envelope, or complete it online. Informed consent was taken from all participants. Some patients were 
recruited through a postal invitation sent out by clinic staff to eligible patients.  Online advertisements 
were placed on patient support websites and Facebook groups. When a participant saw this 
advertisement, they contacted the researcher who gave them information about the study and screened 
them for eligibility. They were then either posted the questionnaire or given a link to complete it 
online. The questionnaire took between 20 – 30 minutes to complete.  
Measures  
Sociodemographic and clinical variables 
Participants provided data on demographic (age, ethnicity, relationship status, employment status, 
age left full time education, menopausal status at diagnosis), clinical (breast cancer stage, previous 
treatment, comorbidities) and treatment related factors (date prescribed tamoxifen, duration of 
tamoxifen treatment, type of prescribing clinician).  
Social Support  
Social support was measured using the Multidimensional Scale of Perceived Social Support 
(Zimet, Dahlem, Zimet, & Farley, 1988). Each item was scored on a seven point scale, with higher 
scores indicating higher levels of support. The scale has demonstrated good internal and test-retest 
reliability and has been used successfully to measure social support in patients with breast cancer 
(Oztunc, Yesil, Paydas, & Erdogan, 2013). Internal consistency in the current study was 0.96. 
 
Distress  
Distress, measured using The Hospital Anxiety and Depression Scale (HADS), was included as a 
covariate (Zigmond & Snaith, 1983). The scale includes seven items measuring depression and seven 
measuring anxiety. Following recent recommendations, the scale was used as a measure of general 
distress (Norton, Cosco, Doyle, Done, & Sacker, 2013).  The scale showed good reliabity in the 
current study (α=.91). 
Side effects  
The FACT-ES is a quality of life scale for patients with breast cancer taking HT (Fallowfield, 
Leaity, Howell, Benson, & Cella, 1999). The additional concerns subscale was used to measure side-
effects. Patients provide an answer on a five point scale from ‘not at all’ to ‘very much’ to indicate 
how much they have experienced each side-effect for a list of 18 side effects. This provides a 
combined measure of both number and intensity of side-effects, representing the overall level of 
bother from side effects.  The subscale showed good reliability in the current study (α =.87). 
Information about treatment 
To assess how informed patients are about their treatment, they were asked the extent to which 
they agreed or disagreed with four statements, such as “I feel confident in my understanding of how 
tamoxifen helps me”. The scale showed good reliability (α =.89) in the current study.    
Illness representations  
The IPQ-BCS (Moon, Moss-Morris, Hunter, & Hughes, 2017), a modified version of the Revised 
Illness Perceptions Questionnaire, was used to measure components of the CSM. The scale has good 
psychometric properties and includes ten subscales; cure, risk of recurrence, tamoxifen consequences, 
breast cancer consequences, personal control, treatment control, illness coherence, emotional 
representations, tamoxifen identity and causes of recurrence.  The subscales have previously 
demonstrated good internal reliability with Cronbach’s alphas ranging from .76 to .92. Each scale 
includes four items scored on a 5-point Likert-type scale, with the exception of the tamoxifen identity 
and causes of recurrence scales. The identity scale includes a list of symptoms where participants 
indicate if they have experienced each symptom and if they attribute it to their tamoxifen treatment. 
The scale is scored by summing the number of symptoms attributed to tamoxifen. The causes of 
recurrence scale includes 14 possible causes. A previous exploratory factor analysis has indicated two 
factors for causes; psychological attributions (e.g. my emotional state) and health behaviours (e.g. diet 
or eating habits) (Moon et al., 2017).   
Beliefs about Medicines   
Beliefs about Medicines were measured as part of the extended CSM, which has particular 
relevance for medication adherence. The BMQ-Specific was used to measure beliefs regarding the 
necessity of taking tamoxifen and concerns about adverse effects. The scale has previously shown 
good psychometric properties (Horne, Weinman, & Hankins, 1999). A differential score was 
calculated by taking the total score for concerns away from the total score for necessity beliefs, as 
recommended by the authors of the BMQ (Horne & Weinman, 1999). A positive differential suggests 
that the necessity beliefs outweigh the concerns.  
Theory of Planned Behaviour  
Items relating to TPB variables were developed following guidelines from Francis et al. (2004) 
and Ajzen (2002). Subscales include intention to take tamoxifen, subjective norms, attitude and PBC. 
Intention, subjective norm and PBC were measured on a 7-point Likert scale. Attitudes were 
measured with five semantic differential scales scored on a ten point scale. Each subscale showed 
good reliability in the current study (α= 0.67 – 0.82), with the exception of subjective norms (α= 
0.52), however all subscales were included in order to fully test the model.  
Adherence 
The Medication Adherence Report Scale (MARS; Horne, Hankins, & Jenkins, 2001) includes five 
statements about taking medication, which are each scored on a five point scale from never to always. 
The scale attempts to avoid any issues regarding social desirability by asking questions in a non-
threatening and non-judgemental way. The scale has demonstrated good internal reliability and test-
retest reliability and has been used multiple times in breast cancer patients (Boonstra et al., 2013). 
Scores on the MARS were strongly positively skewed and therefore the data was dichotomised based 
on recommendations from previous papers (de Vries et al., 2014). The MARS includes a one item 
sub-scale on unintentional non-adherence (total score of 5) and a four item sub-scale on intentional 
non-adherence (total score of 20), with a total possible overall adherence score of 25. On the basis of 
previous studies, participants were classed as unintentionally non-adherent if they scored below 5 and 
intentionally non-adherent if they scored below 20 on the respective sub-scales (Daleboudt et al., 
2011; Timmers et al., 2014; de Vries et al., 2014). Participants could be classed as both intentionally 
and unintentionally non-adherent.  
Statistical analysis 
Relationships between hypothesized correlates and intentional/unintentional non-adherence were 
tested using Cramer’s V for categorical variables and biserial correlations for continuous variables.  
Separate multiple logistic regressions were carried out to assess the relationships between intentional 
and unintentional non-adherence and components of the CSM and TPB. Clinical, demographic and 
potentially confounding psychosocial variables which showed a significant bivariate relationship with 
non-adherence were entered into the first step of the regression models. The CSM and TPB 
components were entered into the next step, to assess their impact on adherence after the demographic 
variables have been taken into account. The ability of components from each model to explain non-
adherence was assessed using Nagelkerke R2 (pseudo R2) to measure the proportion of variance 
explained.  Model fit was also assessed by the -2 Log Liklihood statistic (-2LL). Lower -2LL values 
indicate superior model fit, and therefore if the addition of variables reduces the -2LL value, the 
variables have improved the model fit. The reduction in the -2LL statistic for each step is represented 
by chi-squared. T-tests using Bonferroni correction were used to compare women in their first year of 






Demographics of sample  
1246 women were invited to participate from clinics and 758 women completed the questionnaire 
(61% response rate). An additional 60 women were recruited through online advertising. Forty-one 
(5%) women reported having discontinued tamoxifen and were removed from the sample. The final 
sample included 777 women. All participants were female, had Stage I-III breast cancer and had been 
prescribed tamoxifen (Table 1). The mean age was 53 (SD=10, range 30-90). Participants were mostly 
White British (86%), married (58%) and employed (65%). Just under half of patients had been 
prescribed tamoxifen less than one year ago, 22% 1-2 years ago and 31% over two years ago. Two 
thirds of participants self-reported being premenopausal or menopausal at time of diagnosis.  
Adherence rates 
Non-adherence was rated using cut-offs on the MARS. 44% (n=340) showed any sign of non-
adherence, 9% (n=71) reported intentional non-adherence and 41% (n=321) reported unintentional 
non-adherence.  
Explanatory variables  
Means and SDs for each subscale are shown in Table 2. Mean anxiety levels (6.9, SD=4.4) were 
higher than depression rates (4.1, SD=3.8) but both were within normal ranges for the general 
population. The mean distress score was 11.0 (SD=7.5). Participants had relatively high beliefs in 
treatment control (mean=15.3, SD=2.5), illness coherence (mean=15.4, SD=2.9) and cure 
(mean=15.7, SD=3.0). An average of 5.6 symptoms were attributed to tamoxifen (SD=4.9).  BMQ 
differentials were slightly above 0, showing that on average, participants had positive necessity-
concern differentials (2.1, SD=5.2). Mean scores for intentions (6.5, SD=1.2), subjective norm (6.0, 
SD=1.0) and PBC (6.2, SD=1.0) were all high and attitudes were positive (7.9, SD=1.7).   
Intentional non-adherence  
The only demographic or clinical variables associated with intentional non-adherence were 
previously having a double mastectomy (Cramer’s V=.10, p=.01) and months since prescribed 
tamoxifen (rb=.17, p=.01) (See supplementary material, Appendix E). Side-effect intensity (rb=.44, 
p<.001), distress (rb=.37, p<.001), social support (rb =-.19, p=.013) and how informed participants 
were (rb=-.13, p=.030) were also associated with intentional non-adherence and were entered into the 





Table 1. Participant demographics. 
Characteristic  N (%) 
Age 30 – 90             Mean: 53 (SD: 10) 
Ethnicity  666 (86%) White British 
110 (14%) Other  
Relationship status 555 (72%) With partner  
218 (28%) Separated /Divorced /Single/Widowed   
Job status  504 (65%) Employed full time / part time 
209 (28%) Retired / Homemaker / Other  
61 (8%) Unemployed  
Time since prescribed 
tamoxifen 
< 6 months: 206 (28%) 
6 – 12 months: 142 (19%) 
1 – 2 years: 162 (22%) 
2 – 3 years: 99 (13%) 
3 – 4 years: 61 (8%) 
>4 years: 75 (10%)  
Stage at diagnosis Stage I: 308 (40%) 
Stage II: 326 (43%) 
Stage III: 93 (12%) 
Unsure: 35 (5%) 
Missing: 14 (2%) 
Menopausal status at 
diagnosis 
Pre-menopausal/menopausal: 511 (67%) 
Post-menopausal: 212 (28%) 
Unsure: 35 (5%) 
Missing: 18 (2%) 
Previous treatment Lumpectomy: 63% 
Single Mastectomy: 34% 
Double Mastectomy: 6% 
Chemotherapy: 51% 
Radiotherapy: 73%  
Tamoxifen duration One or two years: 16 (2%) 
Five years: 496 (64%) 
Ten years: 190 (25%) 
For life: 1 (0.1%) 
Unsure: 40 (5%) 
Missing: 26 (3%) 
Healthcare professional 
who prescribed tamoxifen  
Oncologist: 595 (77%) 
Surgeon: 130 (17%) 
Nurse: 24 (3%) 
GP: 5 (1%) 










Table 2. Relationship between explanatory variables and non-adherence 












2.10 (5.23) -20 - 20  -0.44*** -0.18*** 
Tamoxifen consequences  10.06 (4.09) 4 – 20 0.49*** 0.12** 
Breast cancer 
consequences  
12.11 (3.71) 4 – 20 0.21*** 0.07 
Risk of recurrence 10.48 (3.45) 4 – 20 0.00 0.04 
Cure  15.66 (3.04) 4 – 20 -0.08 0.04 
 Personal control  13.73 (3.01) 4 - 20 -0.07 0.09 
Treatment control  15.32 (2.46) 6 - 20  -0.09 0.02 
 Coherence 15.38 (2.86) 4 - 20 -0.06 0.01 
Emotional representations 13.23 (4.30) 4 - 20 0.08 0.07 
Attributing side effects to 
tamoxifen 
5.75 (4.87) 0 – 22  0.38*** 0.19*** 
Cause: psychological 
attributions 
9.52 (2.87) 3 - 15  0.23*** 0.09 
Cause: health factors   13.15 (2.99) 4 - 20 -0.03 0.10* 
Attitude 7.86 (1.66) 1 – 10 -0.35*** 0.14** 
 Intention 6.46 (1.18) 1 -7  -0.69*** 0.22*** 
Subjective norm  6.03 (1.03) 1 – 7 -0.19** 0.14** 
Perceived behavioural 
control  
6.18 (1.02) 1-7  -0.70*** 0.22*** 
*** p≤.001, **p<.01, *p<.05 
 
CSM components associated with intentional non-adherence in the bivariate analysis were; BMQ 
differential, tamoxifen consequences, breast cancer consequences, cause: psychological attributions 
and tamoxifen identity.  From the TPB; intention, subjective norm and attitude were all associated 
with intentional non-adherence (Table 2). Two logistic regressions were conducted to test separately 
the measured components of the CSM and TPB and a third regression combined the CSM and TPB 
variables. The model combining both the CSM and TPB variables explained the most variance in 
intentional non-adherence (Nagelkerke R2=46%) (Table 3). In this model, the variables in Step 1 
explained 20% of the variance (χ2(5) = 60.06, p<.001, R2=20%). Higher levels of distress (OR=1.06, 
95% CI=1.02-1.11) and higher intensity of side-effects (OR=1.05, 95% CI=1.03-1.08), having a 
double mastectomy (OR=3.18, 95% CI=1.33-7.60) and a longer duration of tamoxifen prescription 












 OR 95% CI OR 95% CI OR 95% CI 
Step 1        
   Side effect intensity  1.02 0.99 – 1.05 1.03 1.00 – 1.06 1.01 0.98 – 1.05 
   Social support 0.99 0.76 – 1.28 1.01 0.77 – 1.31 0.94  0.70 – 1.26 
   Extent patients feel 
informed about 
tamoxifen  
0.95 0.87 – 1.05 1.01 0.91 – 1.11 1.03 0.91 – 1.15 
   Distress 1.04 0.99 – 1.09 1.03 0.98 – 1.09 1.05 0.99 – 1.12 
   Months since 
prescribed  
1.01 0.99 – 1.03 1.01 0.99 – 1.02 1.01 0.99 – 1.03 
   Double Mastectomy 
(received)  
3.55 1.37 – 9.18 5.35 2.07 – 13.88 6.41 2.26 – 18.19 
Step 2           
Necessity/concerns 
differential 
0.89 0.83 – 0.95   0.97 0.89 – 1.06 
   Tamoxifen 
consequences  
1.15 1.04 – 1.27   1.06 0.94 – 1.19 
   Breast cancer  
consequences  
0.96 0.87 – 1.08   0.93 0.81 – 1.05 
   Risk of recurrence 0.88 0.80 – 0.97   0.87 0.76 – 0.98 
   Cure  0.94  0.84 – 1.06   0.96  0.84 – 1.10 
   Personal control  0.93 0.81 – 1.05   0.97 0.85 – 1.12 
   Treatment control  1.10 0.92 – 1.23   1.05 0.86 – 1.28 
   Coherence 1.02 0.91 – 1.17   1.01 0.87 – 1.16 
  Emotional 
representations 
0.93  0.86 – 1.03   0.96  0.86 – 1.07 
   Attribution of 
symptoms to tamoxifen 
1.03 0.95 – 1.09   1.05 0.96 – 1.14 
   Cause: psychological 
attributions 
2.06 1.34 – 3.05   2.28 1.40 – 3.71 
   Cause: health 
behaviours   
0.58 0.40 – 1.01   0.41 0.24 – 0.72 
   Attitude   1.15 0.90 – 1.47 1.29 0.98 – 1.70 
   Intention   0.69 0.53 – 0.89 0.72 0.53 – 0.98 
   Subjective norm    1.19 0.86 – 1.63 1.11 0.78 – 1.58 
  Perceived 
behavioural control  
  0.43 0.30 – 0.62 0.37 0.24 – 0.56 
 
Step 1 -2LL: 
353.3 
Step 1 R2 = .19 
Step 1 χ2 = 62.1 
(p<.001) 
 
Step 2 –2LL: 
302.79 
Step 2 R2 = .34 
Step 2 Δχ2 (12) = 
50.52 (p<.001)  
Step 2 –2LL: 279.9 
Step 2 R2 = .39 
Step 2 Δχ2 (4) = 64.4 
(p=.000)  
Step 1 -2LL: 332.3 
Step 1 R2 = .20 
Step 1 χ2 =60.06 
(p<.001) 
 
Step 2 –2LL: 243.1 
Step 2 R2 = .46 
Step 2 Δχ2 (16) = 
89.4 (p=.000) 
 
Adding the CSM and TPB variables significantly improved the model fit and explained a further 26% 
of the variance (Δχ2(16) = 89.4, p<.001, R2=46%). After adding these variables, the only variable in 
step 1 still significantly associated with non-adherence was double mastectomy (OR=6.41, 95% 
CI=2.26-18.20). In terms of CSM variables, stronger beliefs in the risk of recurrence (OR=0.87,95% 
CI=0.76-0.98) and stronger beliefs that health behaviours cause a recurrence were associated with 
decreased odds of non-adherence (OR=0.41, 95% CI=0.24-0.72), whereas beliefs that stress caused a 
recurrence were associated with two-fold increased odds of non-adherence (OR=2.28, 95% CI =1.40 
– 3.71). Higher levels of PBC (OR=0.37, 95% CI=0.24-0.56) and intention (OR=0.73, 95% CI=0.52-
0.98) were associated with decreased odds of intentional non-adherence.  
Unintentional non-adherence  
Individual associations between adherence and variables were tested using Cramer’s V and biserial 
correlations. There were small but significant relationships between unintentional non-adherence and 
ethnicity (Cramer’s V =.09, p=.007), relationship status (Cramer’s V=.13, p=.007) and menopausal 
status (Cramer’s V=.15, p =.001). There was a moderate relationship between job status and 
unintentional non-adherence (Cramer’s V=.22, p<.001) and a weak relationship between previous 
chemotherapy and unintentional non-adherence (Cramer’s V=.08, p=.038) (See supplementary 
material).  Age (rb=.22, p<.001), age left full time education (rb=.12, p=.006), side-effect intensity 
(rb=.14, p<.001), social support (rb=-.14, p=.007) and months since prescribed (rb=.21, p<.001) were 
correlated with unintentional non-adherence. In terms of variables from the CSM, unintentional non-
adherence was associated with; necessity/concerns differential, tamoxifen consequences, tamoxifen 
identity and cause: health behaviours. TPB variables associated with unintentional non-adherence in 
the bivariate analysis were PBC, intention, subjective norm and attitudes (Table 2). 
Separate logistic regressions were carried out to test the measured components of the CSM, the TPB 
and then a combination of CSM and TPB variables. The model including the CSM variables and the 
model including a combination of CSM and TPB variables both explained 17% of the variance in 
unintentional non-adherence (Table 4). Control variables were entered in step one, explaining 13% of 
the variance in unintentional non-adherence (Δχ2(10) = 53.1, p<.001, R2=13%). Women who were 
white (OR=0.48, 95% CI=0.24-0.99) or older (OR=0.97, 95% CI=0.94-0.99) had lower odds of non- 
adherence and women who were employed (OR=2.08, 95% CI=1.32-3.30) or had been taking 
tamoxifen longer (OR=1.02, 95% CI=1.01-1.03) had higher odds of non-adherence. Adding variables 
from the CSM/TPB in the second step of the model explained a further 4% of variance, but did not 

















 OR 95% CI OR 95% CI OR 95% CI 
Step 1        
   Side effect intensity  1.01 0.99-1.03 1.01 0.99-1.02 1.00 0.98-1.03 
   Social support 0.88 0.75-1.02 0.91 0.79-1.06 0.89 0.76-1.03 
   Ethnicity (white) 0.43 0.21-0.88 0.53 0.26-1.07 0.43 0.20-0.91 
   Age 0.96 0.93-0.99 0.97 0.95-1.00 0.97 0.94-1.00 
   Relationship status 
(with partner) 
0.73 0.47-1.11 0.77 0.51-1.17 0.74 0.48-1.16 
   Employment status  
(employed)  
2.16 1.37-3.38 2.12 1.95-3.33 2.10 1.30-3.39 
   Months since 
prescribed  
1.02 1.01-1.03 1.02 1.01-1.03 1.02 1.01-1.03 
   Chemotherapy 
(received)  
0.99 0.66-1.50 0.93 0.63-1.39 1.01 0.66-1.54 
   Age left full time 
education 
0.99 0.93-1.05 1.02 0.96-1.08 0.98 0.92-1.05 
   Menopausal status 
(premenopausal)  
0.66 0.40-7.09 0.83 0.51-1.34 0.69 0.38-1.10 
Step 2           
   Necessity/concerns 
differential 
0.96 0.93-1.00   0.97 0.93-1.02 
   Tamoxifen 
consequences  
1.00 0.94-1.07   0.98 0.92-1.05 
   Breast cancer 
consequences  
0.98 0.92-1.05   0.97 0.91-1.04 
   Risk of recurrence 0.98 0.92-1.05   0.98 0.91-1.05 
   Cure  1.01 0.95-1.09   1.03 0.96-1.11 
   Personal control  1.01 0.93-1.10   1.03 0.95-1.12 
   Treatment control  1.04 0.94-1.16   1.03 0.92-1.15 
   Coherence 1.02 0.94-1.09   1.04 0.96-1.12 
   Emotional 
representations 
1.01 0.96-1.07   1.02 0.96-1.08 
   Symptoms attributed to 
tamoxifen  
1.03 0.98-1.08   1.03 0.98-1.09 
   Cause:  psychological 
stress 
1.04 0.82-1.31   1.08 0.85-1.38 
   Cause: health 
behaviours   
1.21 0.89-1.63   1.07 0.78-1.46 
   Attitude   0.95 0.84-1.08 0.96 0.84-1.10 
   Intention   1.01 0.82-1.25 1.03 0.82-1.28 
   Subjective norm    0.95 0.79-1.15 0.99 0.80-1.21 
   Perceived behavioural 
control  
  0.80 0.63-1.02 0.78 0.60-1.01 
 
Step 1 -2LL: 
719.4 
Step 1 R2 = .15 
Step 1 χ2 (10) = 
65.65 (p<.001) 
 
Step 2 –2LL: 
706.9 
Step 2 R2 = .17 
Step 2 Δχ2 (12) = 
12.5 (p=.405)  
Step 1 -2LL: 729.0 
Step 1 R2 = .13 
Step 1 χ2 (10) = 
56.1 (p<.001) 
 
Step 2 –2LL: 721.4 
Step 2 R2 = .14 
Step 2 Δχ2 (4) = 7.6 
(p=.108)  
Step 1 -2LL: 680.1 
Step 1 R2 = .13 
Step 1 χ2 (10) = 53.1 
(p<.001) 
 
Step 2 –2LL: 662.3 
Step 2 R2 = .17 
Step 2 Δχ2 (16) = 
17.9 (p=.331)  
 
Adherence rates and perceptions in newly prescribed patients  
Compared to women not in their first six months since prescription, women in their first six months of 
tamoxifen prescription reported lower levels of distress (t(427)=-3.04, p=.003) and less intense side-
effects (t(427) = -6.76, p=<.001) (Table 5). They also had higher intentions to take tamoxifen 
(t(627)=2.36, p=.003) and a more favourable attitude towards tamoxifen (t(663)=2.20, p=.028). With 
regards to illness/treatment beliefs, women within six months of prescription had lower scores on 
tamoxifen consequences (t(743) = -4.33, p=<.001), attributed fewer symptoms to tamoxifen (t(489)= 
5.94, p=<.001) and were less likely to believe they were cured (t(316) = -3.36, p=.001). Women in 
their first six months of treatment also had significantly higher overall adherence rates (t(743) =-2.33, 
p=.020). However, adherence scores and attitudes were no longer significantly different after 
Bonferroni correction.  
 
Table 5. Descriptive statistics and t-tests to compare women in their first six months of treatment 























* Relationship remained significant after Bonferroni correction.  
 
 
Women in their first 
six months of 
treatment (n=206) 
(range 1 – 6 months) 
 
Mean (SD)  
Women not in their 
first six months of 
treatment (n=539) 
(range 6 months – 8 
years) 
Mean (SD) 
p value   
MARS scores  24.34 (1.44) 24.01 (1.76) .020 
Necessity/concerns differential  2.50 (5.36) 1.98 (5.24) .233 
Tamoxifen consequences  9.09 (3.56) 10.45 (4.26) <.001* 
Breast cancer consequences  12.33 (3.59) 12.03 (3.80)  .338 
Risk of recurrence 10.41 (3.41) 10.52 (3.51) .703 
Cure  15.01 (3.41) 15.92 (2.84) .001 * 
 Personal control  13.59 (3.16) 13.82 (2.98) .366 
Treatment control  15.41 (2.49) 15.34 (2.42) .722 
 Coherence 15.14 (2.98) 15.53 (2.78) .099 
Emotional representations 13.27 (4.20) 13.28 (4.33) .982 
Attributing side effects to 
tamoxifen 
4.36 (3.79) 6.41 (5.09) <.001 * 
Attitude 8.09 (1.45) 7.78 (1.71) .028 
 Intention 6.63 (0.75) 6.41 (1.28) .003 * 
Subjective norm  6.12 (0.98) 5.98 (1.04) .097 
Perceived behavioural control  6.28 (0.90) 6.14 (1.07)  0.73 
Distress 23.73 (6.70) 25.48 (7.78) .003 * 
Side effect intensity 35.11 (11.23) 41.62 (13.03) <.001 * 
Discussion 
This study explored associations between key components of the CSM and TPB with 
intentional and unintentional tamoxifen non-adherence. This is one of the largest studies to date to 
investigate psychosocial correlates of tamoxifen non-adherence and to use validated models of health 
behaviour as a framework. Results showed that key elements from both theories provide a useful 
framework for investigating intentional non-adherence. Drawing key variables from both the CSM 
and TPB provided the best explanation of intentional non-adherence, but these variables were not able 
to improve the explanation of unintentional non-adherence over and above clinical and demographic 
factors. Just under half of the sample were found to be non-adherent, with much higher percentages 
for unintentional than intentional non-adherence, as hypothesised. The figure of around 44% non-
adherence has been found in many other studies of HT non-adherence (Kimmick, Camacho, Hwang, 
& Anderson, 2009; Lee et al., 2014; Seneviratne et al., 2015). Other studies have also supported the 
finding of higher rates of unintentional rather than intentional non-adherence (Kimmick et al., 2015; 
Tinari et al., 2015; Wouters et al., 2014). However, it is currently unclear if this reflects truly higher 
rates or the fact that forgetting may be more socially acceptable and is therefore endorsed more 
frequently by respondents (Atkins & Fallowfield, 2006). The current study identified unique 
correlates of intentional and unintentional non-adherence, and found poor prediction of unintentional 
non-adherence by psychological models. This suggests that these two types of non-adherence may be 
distinct from each other, and that participants are not simply reporting unintentional non-adherence as 
it is more socially acceptable. 
 
The model combining both CSM and TPB variables provided the best fit for intentional non-
adherence, explaining 46% of the variance. This combined model has been useful previously in 
predicting other health behaviours such as help seeking for breast symptoms (Hunter, Grunfeld, & 
Ramirez, 2003) and cervical cancer screening (Orbell, Hagger, Brown, & Tidy, 2006). 
Conceptualising these sets of beliefs together provides the best understanding of intentional non-
adherence and is likely to be the best way to improve adherence. The results suggest that attitudes and 
perceptions around medication taking, as assessed by the TPB, and perceptions of breast cancer 
survivorship, as assessed by the CSM, are both central to understanding medication adherence. This 
highlights the importance of illness perceptions in breast cancer survivors and builds upon previous 
research using the CSM. Whilst women are no longer currently ill, their illness perceptions around 
survivorship and previous treatment are related to adherence. A recent review has found some 
evidence that interventions based on the CSM can improve adherence to a range of health behaviours, 
but concluded that more research was needed (Jones, Smith, & Llewellyn, 2015). Whilst intentional 
non-adherence is reported less often than unintentional non-adherence, this behaviour is likely to be 
harder to modify and it is therefore of great interest that the CSM/TPB provide good explanation of 
this behaviour. Intentional non-adherence is also more likely to lead to discontinuation and therefore 
has strong clinical implications. 
 
High risk of recurrence beliefs were associated with decreased odds of intentional non-
adherence, probably because the fear of recurrence keeps women motivated to take tamoxifen. 
Stronger beliefs that psychological stress would cause a recurrence were associated with increased 
odds of non-adherence.  If women endorse stress as a cause of recurrence then they may feel that there 
is no benefit in taking tamoxifen, as it does not control their stress levels.  The necessity/concerns 
differential and tamoxifen consequences were significantly related to intentional non-adherence in the 
CSM model. This supports previous research suggesting that how people weigh up the necessity and 
concerns of treatment are related to whether or not they adhere (Horne & Weinman, 1999; Wileman et 
al., 2011). However the necessity/concerns differential and tamoxifen consequences were not 
significant once TPB variables were added, suggesting they may share variance with intention or 
PBC. Higher levels of PBC and intention were associated with decreased odds of intentional non-
adherence. This is consistent with previous studies and theory (Bane et al., 2010) and suggests that 
interventions to improve PBC may help to improve adherence in this population. For example, 
implementation intentions, which are if-then goal plans where patients specify “I intend to do X at 
time Y in location Z”, have been effective at increasing cervical cancer screening uptake (Sheeran & 
Orbell, 2000) and improving adherence in stroke survivors (O'Carroll, Chambers, Dennis, Sudlow, & 
Johnston, 2013).  
 
Side-effects and distress were related to increased intentional non-adherence, but not when 
controlling for CSM and TPB variables. This is consistent with previous research which has found 
inconclusive evidence for the relationship between side-effects and non-adherence (Moon et al., 
2017). Evidence suggests that women weigh up their necessity beliefs against their concerns when 
making decisions about taking tamoxifen (Fink, Gurwitz, Rakowski, Guadagnoli, & Silliman, 2004). 
If women have strong beliefs in the necessity of tamoxifen, they may continue to take it, regardless of 
side-effects. The results from the current study support this by showing that illness or treatment 
beliefs are stronger correlates of non-adherence than side-effects alone. This highlights the need to 
modify these psychological factors alongside side-effect management.  
 
Women who had a double mastectomy were six times more likely to be intentionally non-
adherent than women who did not have a double mastectomy, even after controlling for psychological 
variables. This may reflect a decision made by patients where they feel that tamoxifen is less 
necessary for them after removal of all breast tissue.  A woman’s choice to undergo a double 
mastectomy is a complex decision and is associated with a range of factors, such as treatment 
concerns (Molenaar et al., 2014) and fear of cancer recurrence (Nold et al., 2000). Therefore the 
relationship between non-adherence and receipt of double mastectomy may also be driven by one of 
these factors.  
 
The fact that the majority of clinical and demographic variables were not related to intentional 
non-adherence supports the findings of a recent review showing few consistent clinical or 
demographic predictors of non-adherence (Moon et al., 2017). This lack of clear factors on which to 
screen patients for non-adherence highlights the importance of investigating psychological factors as 
potential avenues for intervention. Results from this study suggest that utilising the key variables 
drawn from the models concurrently will give researchers and practitioners the best chance at 
improving adherence rates. Non-adherence appears to be related to perceptions around cancer as well 
as perceptions of control over medication taking. Therefore interventions which focus solely on one of 
these factors may miss out on key predictors of non-adherence.  
 
However, whilst these psychological models provided good explanation for intentional non-
adherence, adding CSM and TPB variables did not improve the prediction of unintentional non-
adherence. Furthermore, study variables were only able to explain 17% of the variance in 
unintentional non-adherence, compared to 46% for intentional non-adherence. Therefore, more 
research is needed to improve understanding of unintentional non-adherence to tamoxifen. Some 
interventions have shown success at improving adherence using reminders or action plans (Brown, 
Sheeran & Reuber, 2009; O’Carroll et al., 2013; Webb & Sheeran, 2006), but as yet, no studies have 
attempted to improve unintentional non-adherence in women taking tamoxifen.  
 
Whilst there were small correlations between medication beliefs and unintentional non-
adherence, these relationships were not maintained in the regression analysis. This contrasts with 
previous research showing that unintentional non-adherence is predicted by medication beliefs 
(Gadkari & McHorney, 2012; Schüz et al., 2011). However, a recent study found that medication 
beliefs were associated with intentional but not unintentional non-adherence to HT (Brett et al., 2016), 
supporting the results of the current study. This suggests that unintentional non-adherence in this 
population may be influenced slightly by a patient’s medication beliefs, but is much more likely to be 
due to forgetting or not establishing a good medication taking routine. This is further supported by the 
identification of unique predictors of both intentional and unintentional non-adherence.   
 
 Unintentional non-adherence was associated with demographic and clinical variables. 
Women who were white were less likely to be non-adherent than women who were not white, 
however the proportion of women of other ethnicities was small. Women who were older had higher 
odds of adherence, which has also been found in previous studies (Brett et al., 2016; Jacob Arriola et 
al., 2014; Kimmick et al., 2015) and may reflect the fact that young women may have difficulties 
setting a routine around work or raising a family. Women who were employed had higher odds of 
non-adherence, independent of the effects of age. This supports findings of recent studies in HT 
adherence (Brett et al., 2016; Quinn, Fleming, & O’Sullivan, 2016) and may be due to practical 
problems, such as experience of side-effects in the workplace. Women with a longer time since 
tamoxifen initiation also had higher odds of non-adherence, which is supported by studies showing 
that non-adherence rates increase over time (Lee et al., 2014; Wu et al., 2012). These results help to 
identify women who are at higher risk of unintentional non-adherence, and who may need further 
support in taking their medication, such as women in the workforce or women from minority ethnic 
groups. However, more research on these relationships is necessary before any specific 
recommendations can be made for improving adherence in these subgroups, especially with regards to 
the results around ethnicity. Results indicate unique correlates of intentional and unintentional non-
adherence in this population, suggesting interventions tailored to the type of non-adherence may be 
necessary.  
 
Women in their first six months since prescription showed more favourable beliefs and 
perceptions towards tamoxifen than those later in the treatment pathway. They have higher intentions 
to take tamoxifen, lower distress scores, lower scores on tamoxifen consequences and attributed fewer 
side-effects to tamoxifen. These results suggest that it may be beneficial to intervene early before 
women’s intention to take tamoxifen decreases and to help them successfully manage their side 
effects early on. Interestingly, many of the illness perceptions were not significantly different which 
suggests beliefs may not change over the course of treatment, which is contrary to the self-regulation 
proposed by the CSM. However, longitudinal research is needed to confirm this.  
 
This study included a large nationwide sample and is, to the best of our knowledge, the first 
study to investigate correlates of tamoxifen non-adherence from the CSM and TPB. However, there 
were several limitations to the study. Adherence was measured by self-report, which may over-
estimate adherence rates due to recall bias or socially-desirable answering. However, the MARS has 
been shown to correlate with more objective measures (O'Carroll et al., 2013), and non-adherence 
rates found in this study were comparable to studies using prescription refill rates (Partridge et al., 
2003; Seneviratne et al., 2015). Taking less than 80% of prescribed doses is associated with decreased 
odds of survival in breast cancer patients (Hershman et al., 2011).  Unfortunately we could not 
operationalise non-adherence in this way so it is unclear if the levels of non-adherence in this study 
are related to survival. Due to the cross-sectional design, it was also not possible to identify factors 
related to non-persistence. Future research should assess if the CSM and the TPB provide good 
explanation for non-persistence.   We only tested illness and emotional representations within the 
CSM and missed other key elements of the model such as assessment of coping behaviours and 
appraisal. Although medication adherence could be seen as a coping behaviour used to control the 
health threat, we did not measure the appraisal of non-adherence as a coping strategy. The study was 
cross-sectional and it therefore limits assumptions about causality. Future research should test these 
models in longitudinal studies. Finally, there may be some selection bias, as the response rate was 
61% and patients who did not take part may be more likely to be non-adherent. 
 
In spite of these limitations, the study makes an important contribution to the literature by 
showing that the CSM and TPB provide a useful framework for understanding intentional non-
adherence to tamoxifen. It highlights the utility of these theories and demonstrates the importance of 
considering both theories concurrently when designing interventions. Results also highlight the extent 
of non-adherence in this population and suggest that unintentional and intentional non-adherence may 
be distinct behaviours with unique correlates. In particular, the study highlights the high proportion of 
unintentional non-adherence. As this behaviour was not explained well by the psychological models, 
there is a need to further understand this behaviour and to develop ways to improve unintentional non-
adherence. Future research should confirm these findings in longitudinal studies and use the CSM and 
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